ArticleStem cell research & therapy2026
CAV1-dependent mitochondrial transfer from hucMSCs reprograms epithelial lipid metabolism to relieve pulmonary fibrosis.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundIdiopathic pulmonary fibrosis (IPF) is characterized by persistent epithelial injury accompanied by mitochondrial dysfunction. Although mesenchymal stem cells (MSCs) can restore epithelial function by donating mitochondria to damaged cells, the molecular mechanisms driving this process remain unclear. In this study, we demonstrate that caveolin-1 (CAV1) enhances mitochondrial transfer from human umbilical-cord-derived MSCs (hucMSCs) to injured epithelial cells.
methodsIn vitro and in vivo bleomycin-induced models were used to evaluate mitochondrial transfer from hucMSCs to alveolar epithelial cells. Confocal microscopy and intravital lung imaging visualized mitochondrial transfer, while flow cytometry quantified transfer efficiency. Proteomic profiling, mitochondrial functional assays, and lipid analyses were conducted to explore CAV1-associated mechanisms and metabolic outcomes.
resultshucMSC treatment restored mitochondrial membrane potential, ATP production, and epithelial cell viability while reducing reactive oxygen species in injured MLE-12 cells. Proteomic analysis showed significant upregulation of CAV1 in hucMSCs cocultured with injured epithelial cells. In the same dataset, differentially expressed proteins were enriched in pathways related to cytoskeletal remodeling and vesicular transport, supporting a role for hucMSC membrane and trafficking dynamics in mitochondrial delivery. Functional validation confirmed that CAV1 overexpression markedly enhanced mitochondrial transfer and restored mitochondrial function, whereas CAV1 knockdown impaired both transfer efficiency and therapeutic outcomes. Mechanistically, transferred mitochondria promoted mitochondria-lipid droplet tethering, boosted fatty acid β-oxidation, and reduced lipid accumulation. CAV1-overexpressing hucMSCs alleviated alveolar epithelial injury and attenuated pulmonary fibrosis.
conclusionsOur findings identify CAV1 as a crucial mediator of hucMSC-mediated mitochondrial transfer, which enhances epithelial repair through mitochondrial donation and metabolic reprogramming. These insights provide a mechanistic foundation for optimizing stem cell-based therapies in pulmonary fibrosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.